Biotech · Private company

Jounce Therapeutics, Inc.

Track this companyFree. Adds Jounce Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials50 recruiting or active

Pipeline programs8From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline8

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid TumorsPHASE1_PHASE2 · COMPLETED · started Jan 12, 2021ClinicalTrials.gov NCT04669899 · fetched Nov 12, 2026
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsPHASE1_PHASE2 · TERMINATED · started Mar 10, 2020ClinicalTrials.gov NCT04319224 · fetched Nov 12, 2026
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerPHASE2 · COMPLETED · started Jun 6, 2019ClinicalTrials.gov NCT03989362 · fetched Nov 12, 2026
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor MalignanciesPHASE1 · COMPLETED · started Dec 6, 2018ClinicalTrials.gov NCT03790488 · fetched Nov 12, 2026
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsPHASE1_PHASE2 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02904226 · fetched Nov 12, 2026